Alirocumab vs Lerodalcibep

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Alirocumab · Praluent

Marketed by Regeneron Pharmaceuticals and partners

Approved in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Weak signal

NCT01507831 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 trial (ODYSSEY LONG TERM) gave alirocumab 150 mg or placebo every 2 weeks for 78 weeks, on top of maximum tolerated statins, to 2,341 patients at high cardiovascular risk. Its registered primary objective and primary outcome are long-term safety and tolerability, which have no formal efficacy test, so the registered primary has no met or missed result. The published paper reports the efficacy end point it pre-specified: LDL cholesterol fell 62 percentage points more with alirocumab than with placebo at week 24 (P<0.001). Sources: CT.gov posted results and the peer-reviewed paper (Robinson et al., N Engl J Med 2015). Its registered primary outcome on ClinicalTrials.gov is "Percentage of Participants Who Experienced Adverse Events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT07477704 (registry estimate)

Reported efficacy

DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7) (met)

Result source: NCT03510884

Lerodalcibep · Lerochol

Marketed by LIB Therapeutics and partners

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall protein (recombinant fusion protein)
Reliable signal

NCT04797104 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial in 478 patients that measured LDL-cholesterol lowering, the standard efficacy measure for this drug class. Lerodalcibep reduced LDL-C by more than half compared with placebo, a highly statistically significant result.

Next expected readout: July 2028 · NCT07102511 (registry estimate)

Reported efficacy

Change from baseline compared to placebo in LDL-C level (24 weeks): LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001) (met)

Result source: NCT04797104

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlirocumabLerodalcibep
LDL-C, % change-52.7% vs -0.3%−52.4 vs placebo300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144NCT01926782
165 other results
  • -58.8% vs -0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · primary NCT01926782
  • -45.7% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · primary NCT01617655
  • -48.2% vs -2.3% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · primary NCT01644175
  • -48.8% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · primary NCT01623115
  • -48.7% vs 2.8% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · primary NCT01709500
  • -48.2% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · primary NCT02585778
  • -51.7% vs 4.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · primary NCT02023879
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · primary NCT03156621
  • -43.8% vs -4.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · primary NCT02584504
  • -70.1% vs -4.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · primary NCT02584504
  • -50.2% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · primary NCT01926782
  • -51.6% vs -0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · primary NCT01926782
  • -51.8% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · primary NCT02585778
  • -57.1% vs 6.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · primary NCT02289963
  • -62.5% vs 1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · primary NCT02107898
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · primary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · primary NCT03510884
  • -50.6% vs -20.7% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · primary NCT01644188
  • -56% vs -20.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · primary NCT02715726
  • -47.2% vs -15.6% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · primary NCT01644474
  • -45% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · primary NCT01709513
  • -50.6% vs -15.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · primary NCT01730053
  • -36.3% vs -15.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · primary NCT01730053
  • -44.1% vs -5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · primary NCT01730040
  • -54% vs -5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · primary NCT01730040
  • -55.8% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9462 · Phase 3 · secondary NCT01663402
  • -58.3% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9451 · Phase 3 · secondary NCT01663402
  • -45.7% vs 8% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9462 · Phase 3 · secondary NCT01663402
  • -52.8% vs 8.2% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9451 · Phase 3 · secondary NCT01663402
  • -23.5% vs 16.4% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9462 · Phase 3 · secondary NCT01663402
  • -40.1% vs 14.6% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9451 · Phase 3 · secondary NCT01663402
  • -61% vs 0.8% 150 mg Q2W · wk 24 · n 1530 · Phase 3 · secondary NCT01507831
  • -62.8% vs 0.7% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -57.8% vs 3.5% 150 mg Q2W · wk 24 · n 1278 · Phase 3 · secondary NCT01507831
  • -63.3% vs 1.5% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -64.2% vs 1.4% 150 mg Q2W · wk 12 · n 1523 · Phase 3 · secondary NCT01507831
  • -56.8% vs 4.4% 150 mg Q2W · wk 52 · n 1530 · Phase 3 · secondary NCT01507831
  • -59.9% vs 4.6% 150 mg Q2W · wk 52 · n 1523 · Phase 3 · secondary NCT01507831
  • -52.4% vs 3.6% 150 mg Q2W · wk 78 · n 1530 · Phase 3 · secondary NCT01507831
  • -58% vs 3.9% 150 mg Q2W · wk 78 · n 1523 · Phase 3 · secondary NCT01507831
  • -59.4% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -62.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -58.4% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -55.3% vs 1.1% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -60% vs -0.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT01926782
  • -58% vs 1.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 302 · Phase 3 · secondary NCT01926782
  • -49.4% vs 2.7% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -43.5% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -55.1% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -43.8% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -44.2% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -47.1% vs 9% 75 mg/Up to 150 mg Q2W · wk 52 · n 322 · Phase 3 · secondary NCT01623115
  • -40.3% vs 11.5% 75 mg/Up to 150 mg Q2W · wk 78 · n 322 · Phase 3 · secondary NCT01623115
  • -45.5% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -50.7% vs -0.8% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -43.9% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 321 · Phase 3 · secondary NCT01623115
  • -43.7% vs 14% 75 mg/Up to 150 mg Q2W · wk 78 · n 321 · Phase 3 · secondary NCT01623115
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.3% vs 1.1% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -47.6% vs 1.7% 75/150 mg Q2W · wk 12 · n 204 · Phase 3 · secondary NCT01644175
  • -42.1% vs -3% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42% vs -2.9% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42.5% vs 0.5% 75/150 mg Q2W · wk 52 · n 205 · Phase 3 · secondary NCT01644175
  • -49.3% vs 8.8% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -54.6% vs 5.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -43.4% vs -2.8% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -70.1% vs -2.8% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54.2% vs -3.7% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -3.7% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54% vs -2.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -2.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -41.7% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -44.8% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 57 · Phase 3 · secondary NCT02023879
  • -52.3% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · n 58 · Phase 3 · secondary NCT02023879
  • -55% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · n 57 · Phase 3 · secondary NCT02023879
  • -55.3% vs 5.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -50.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 284 · Phase 3 · secondary NCT02585778
  • -43.3% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 277 · Phase 3 · secondary NCT02585778
  • -63.7% vs 1.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -50.8% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -51.5% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -48.8% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 284 · Phase 3 · secondary NCT02585778
  • -44.8% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 275 · Phase 3 · secondary NCT02585778
  • -48.1% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 52 · n 321 · Phase 3 · secondary NCT01623115
  • -40.9% vs -0.2% 150 mg Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -53.8% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -64.2% vs -2.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -62.5% vs -3.6% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -49.4% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -60.2% vs 6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -49.4% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 49 · Phase 3 · secondary NCT02585778
  • -46.7% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 45 · Phase 3 · secondary NCT02585778
  • -57.9% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -58.4% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -64.8% vs -2.8% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -50.3% vs 8.4% 75 mg/up to 150 mg · wk 52 · n 166 · Phase 3 · secondary NCT01709500
  • -64.6% vs -3.4% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -42.3% vs 4% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -53.7% vs 1.6% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -53.6% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -54.1% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -54.6% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -51.8% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -45.3% vs 1.1% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -53.9% vs -0.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -47.3% vs 1.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -37.9% vs 1.2% 150 Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -52.4% vs -21.8% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -51.2% vs -21.8% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -52.4% vs -22.7% 75 /up to 150 mg Q2W · wk 12 · n 464 · Phase 3 · secondary NCT01644188
  • -49.5% vs -18.3% 75 /up to 150 mg Q2W · wk 52 · n 467 · Phase 3 · secondary NCT01644188
  • -51.8% vs -19.7% 75 /up to 150 mg Q2W · wk 52 · n 464 · Phase 3 · secondary NCT01644188
  • -44.2% vs -15.2% 75 /up to 150 mg Q2W · wk 104 · n 467 · Phase 3 · secondary NCT01644188
  • -48.9% vs -17% 75 /up to 150 mg Q2W · wk 104 · n 464 · Phase 3 · secondary NCT01644188
  • -58.7% vs -21.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -57.1% vs -22.2% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -58.1% vs -22.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 401 · Phase 3 · secondary NCT02715726
  • -48.1% vs -19.6% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -52.2% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -47.3% vs -15.2% 75 mg/ up to 150 mg · wk 24 · n 112 · Phase 3 · secondary NCT01709513
  • -47% vs -15.6% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -51.2% vs -18% 75 mg/ up to 150 mg · wk 12 · n 123 · Phase 3 · secondary NCT01709513
  • -53.5% vs -17% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -41.5% vs -17% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -48.6% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -57.8% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -49.6% vs -22.1% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -32.3% vs -22.1% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -52.6% vs -22.9% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -35.1% vs -22.9% 75 mg/up to 150 mg + 20 mg · wk 12 · n 51 · Phase 3 · secondary NCT01730053
  • -48.4% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -50.5% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -53.7% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 52 · Phase 3 · secondary NCT01730040
  • -50.9% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -66.2% vs -51.2% wk 4 · n 31 · Phase 3 · secondary NCT03415178
  • -73% vs 2% wk 2 · n 10 · Phase 4 · primary NCT02938949
  • -54.2% vs 3% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -49.6% vs 0.6% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -51.4% vs 2.8% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -50.4% vs 2.4% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -46.2% vs 4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -43.3% vs -0.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -41.7% vs -7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -64.5% vs -7.6% wk 12 · n 93 · Phase 4 · secondary NCT02984982
  • -63.9% vs -13.4% wk 36 · n 93 · Phase 4 · secondary NCT02984982
-9.3% vs -11%avs evolocumabwk 24NCT04034485
1 other result
  • -53% vs -45.3% wk 38.5714285714 · Phase 3 · primary NCT05004675
Non-HDL-C, % change-51.6% vs 0.7%−52.3 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
87 other results
  • -53.1% vs 0.6% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -53.7% vs 0.9% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -43.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -49.7% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -48.9% vs 0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -52.6% vs 0.2% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -49.9% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -46.5% vs 0.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -42.8% vs 9.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -43.3% vs 9.4% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -38.4% vs 5.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -41.9% vs -6.2% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -41.7% vs -6.1% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -39.1% vs -1.6% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -40.9% vs -0.5% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -41.4% vs -6.9% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -37.4% vs 2.6% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -42.6% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -43.2% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -37.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -44.2% vs 4.8% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -46.7% vs 5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -36.2% vs -4.9% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -4.9% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -35.9% vs -3.5% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -3.5% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -34.9% vs 3% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -45.3% vs 4.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -46.9% vs 5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -45.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -47.2% vs 4.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -50.1% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -54.9% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -56% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -43.4% vs 3% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -47.3% vs 3.9% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -56.3% vs -1.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -35.7% vs 4.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -47.1% vs 2.8% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -41.6% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -37.9% vs 4.1% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -43.6% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -47.2% vs 0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -44.4% vs 0.2% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -45.8% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -37.4% vs 0.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -42.1% vs -19.2% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -43.7% vs -20.2% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -42.6% vs -20.6% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -47% vs -19.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -49.1% vs -20.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -47.4% vs -20.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -40.6% vs -15.1% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -42.5% vs -16.7% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -40.2% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -46.9% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -41.5% vs -15.8% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -42.7% vs -11.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -31.4% vs -11.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -45.7% vs -14.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -35.6% vs -14.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -36.7% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -47.6% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -40.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -50.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -41.2% vs -18% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -29.8% vs -18% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -40.6% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -42.3% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -37.3% vs -4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · primary NCT02642159
  • -37% vs 2.5% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.6% vs 1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -41.1% vs 1.7% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -44% vs 2.2% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.4% vs 0.7% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -35.5% vs -9.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -54.5% vs -14.1% wk 36 · n 93 · Phase 4 · secondary NCT02984982
—Not posted · NCT04790513
ApoB, % change-52.8% vs 1.2%−54 vs placebo150 mg Q2W · wk 24 · n 1468NCT01507831
86 other results
  • -54.3% vs 1.2% 150 mg Q2W · wk 24 · n 1444 · Phase 3 · secondary NCT01507831
  • -55.5% vs 0.5% 150 mg Q2W · wk 12 · n 1468 · Phase 3 · secondary NCT01507831
  • -40.2% vs -0.7% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01926782
  • -45.1% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 292 · Phase 3 · secondary NCT01926782
  • -44.8% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -47.2% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 286 · Phase 3 · secondary NCT01926782
  • -46.4% vs -2.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 138 · Phase 3 · secondary NCT01926782
  • -41.2% vs 3.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 292 · Phase 3 · secondary NCT01926782
  • -41.1% vs 4.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 309 · Phase 3 · secondary NCT01623115
  • -41.4% vs 4.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01623115
  • -34.5% vs 3.1% 75 mg/Up to 150 mg Q2W · wk 12 · n 309 · Phase 3 · secondary NCT01623115
  • -39% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -38.9% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -36.7% vs -0.9% 75/150 mg Q2W · wk 24 · n 185 · Phase 3 · secondary NCT01644175
  • -37.9% vs -0.4% 75/150 mg Q2W · wk 24 · n 181 · Phase 3 · secondary NCT01644175
  • -39.2% vs -9% 150 mg Q2W · wk 12 · n 69 · Phase 3 · secondary NCT01617655
  • -34.8% vs 3.4% 75/150 mg Q2W · wk 12 · n 185 · Phase 3 · secondary NCT01644175
  • -42.8% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 163 · Phase 3 · secondary NCT01709500
  • -43.2% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 162 · Phase 3 · secondary NCT01709500
  • -33.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 279 · Phase 3 · secondary NCT02585778
  • -38.9% vs 7.5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -40.9% vs 7.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 54 · Phase 3 · secondary NCT02023879
  • -32.2% vs -6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -57.9% vs -6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.8% vs -4.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -58% vs -4.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.3% vs 7% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -39.7% vs 7.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -41.2% vs 7.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -39.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -42.3% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 96 · Phase 3 · secondary NCT02289963
  • -45.4% vs 3.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 95 · Phase 3 · secondary NCT02289963
  • -55% vs -1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT02107898
  • -55.9% vs -2.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 140 · Phase 3 · secondary NCT02107898
  • -38.4% vs 7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 112 · Phase 3 · secondary NCT02023879
  • -40.9% vs 5.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 96 · Phase 3 · secondary NCT02289963
  • -54.6% vs -3.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT02107898
  • -33.8% vs 1.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -42.8% vs 1.2% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -36.7% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -35.4% vs -0.9% 75 mg/up to 150 mg · wk 12 · n 163 · Phase 3 · secondary NCT01709500
  • -39% vs -0.7% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 34 · Phase 3 · secondary NCT01926782
  • -42% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -38.3% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 74 · Phase 3 · secondary NCT01926782
  • -40.8% vs -2.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 34 · Phase 3 · secondary NCT01926782
  • -33% vs 3.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -40.7% vs -18.3% 75 /up to 150 mg Q2W · wk 24 · n 452 · Phase 3 · secondary NCT01644188
  • -42.1% vs -19.1% 75 /up to 150 mg Q2W · wk 24 · n 442 · Phase 3 · secondary NCT01644188
  • -39.7% vs -17.2% 75 /up to 150 mg Q2W · wk 12 · n 452 · Phase 3 · secondary NCT01644188
  • -43.5% vs -16.2% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 398 · Phase 3 · secondary NCT02715726
  • -45.2% vs -17.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 392 · Phase 3 · secondary NCT02715726
  • -43% vs -16.5% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 398 · Phase 3 · secondary NCT02715726
  • -36.7% vs -11% 75/Up to 150 mg Q2W · wk 24 · n 48 · Phase 3 · secondary NCT01644474
  • -37.3% vs -11.7% 75/Up to 150 mg Q2W · wk 12 · n 48 · Phase 3 · secondary NCT01644474
  • -36.3% vs -11.2% 75 mg/ up to 150 mg · wk 24 · n 122 · Phase 3 · secondary NCT01709513
  • -42.6% vs -14.4% 75 mg/ up to 150 mg · wk 24 · n 109 · Phase 3 · secondary NCT01709513
  • -36.1% vs -11.6% 75 mg/ up to 150 mg · wk 12 · n 122 · Phase 3 · secondary NCT01709513
  • -36.5% vs -9.8% 75 mg/up to 150 mg + 10 mg · wk 24 · n 44 · Phase 3 · secondary NCT01730053
  • -28.3% vs -9.8% 75 mg/up to 150 mg + 20 mg · wk 24 · n 49 · Phase 3 · secondary NCT01730053
  • -39.5% vs -12.7% 75 mg/up to 150 mg + 10 mg · wk 24 · n 43 · Phase 3 · secondary NCT01730053
  • -30.4% vs -12.7% 75 mg/up to 150 mg + 20 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -33.7% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730040
  • -41.9% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 42 · Phase 3 · secondary NCT01730040
  • -37.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 50 · Phase 3 · secondary NCT01730040
  • -42.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 41 · Phase 3 · secondary NCT01730040
  • -36.1% vs -13.7% 75 mg/up to 150 mg + 10 mg · wk 12 · n 44 · Phase 3 · secondary NCT01730053
  • -29% vs -13.7% 75 mg/up to 150 mg + 20 mg · wk 12 · n 49 · Phase 3 · secondary NCT01730053
  • -38.4% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730040
  • -36.2% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 42 · Phase 3 · secondary NCT01730040
  • -36.4% vs 1.4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -39.1% vs 0.2% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -39% vs 1.1% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.9% vs 2.1% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -36.7% vs 0.8% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -33.8% vs -1.6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.1% vs -16.6% wk 36 · n 92 · Phase 4 · secondary NCT02984982
—Not posted · NCT04790513
Lp(a), % change-29.3% vs -3.7%−25.6 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
64 other results
  • -28.2% vs -3.1% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -21.3% vs 6.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -19.3% vs 9.8% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -28.9% vs -5.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -19.6% vs 7% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -23.5% vs -8.7% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -20.5% vs -5.9% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -23.2% vs -1.5% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -19.7% vs 0% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -25.2% vs -7.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -15.5% vs 4.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -31.7% vs 1.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -49.6% vs 1.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -5.7% vs 2.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -30.3% vs -10% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -21.8% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -19% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -21.2% vs -3.9% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -24.7% vs -5.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -6.1% vs -1.2% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -18.1% vs -4% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -14% vs 6.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -16.9% vs 9.8% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -23% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -35.9% vs -2.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -39.5% vs 2.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -26.9% vs -5.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -12.4% vs 7% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -16.5% vs 2.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -33.6% vs -1.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -41.9% vs -0.5% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16.0% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -27.8% vs -6.1% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -22.1% vs 1.1% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -30.3% vs 4.0% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -30.1% vs 6.3% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -16.7% vs -12.3% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -17.2% vs -14.2% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -25.9% vs -7.3% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -21.7% vs -4.5% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -27.9% vs -5.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -22.7% vs -5.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -23.6% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -30.8% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -20.7% vs 3.5% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -16% vs 3.5% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -24% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -27.9% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -17.7% vs 4.8% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -25.1% vs -1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -24.3% vs -1.4% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -24.7% vs -0.5% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -22.4% vs -3.3% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -23.7% vs 3.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.8% vs -17.2% wk 36 · n 92 · Phase 4 · secondary NCT02984982
—Not posted · NCT04790513
3-point MACE (% with event)—Not posted · NCT04790513—Not posted · NCT04790513

LDL-C, % change

Alirocumab
-52.7% vs -0.3%−52.4 vs placebo300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144NCT01926782
165 other results
  • -58.8% vs -0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · primary NCT01926782
  • -45.7% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · primary NCT01617655
  • -48.2% vs -2.3% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · primary NCT01644175
  • -48.8% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · primary NCT01623115
  • -48.7% vs 2.8% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · primary NCT01709500
  • -48.2% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · primary NCT02585778
  • -51.7% vs 4.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · primary NCT02023879
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · primary NCT03156621
  • -43.8% vs -4.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · primary NCT02584504
  • -70.1% vs -4.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · primary NCT02584504
  • -50.2% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · primary NCT01926782
  • -51.6% vs -0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · primary NCT01926782
  • -51.8% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · primary NCT02585778
  • -57.1% vs 6.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · primary NCT02289963
  • -62.5% vs 1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · primary NCT02107898
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · primary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · primary NCT03510884
  • -50.6% vs -20.7% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · primary NCT01644188
  • -56% vs -20.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · primary NCT02715726
  • -47.2% vs -15.6% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · primary NCT01644474
  • -45% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · primary NCT01709513
  • -50.6% vs -15.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · primary NCT01730053
  • -36.3% vs -15.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · primary NCT01730053
  • -44.1% vs -5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · primary NCT01730040
  • -54% vs -5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · primary NCT01730040
  • -55.8% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9462 · Phase 3 · secondary NCT01663402
  • -58.3% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9451 · Phase 3 · secondary NCT01663402
  • -45.7% vs 8% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9462 · Phase 3 · secondary NCT01663402
  • -52.8% vs 8.2% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9451 · Phase 3 · secondary NCT01663402
  • -23.5% vs 16.4% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9462 · Phase 3 · secondary NCT01663402
  • -40.1% vs 14.6% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9451 · Phase 3 · secondary NCT01663402
  • -61% vs 0.8% 150 mg Q2W · wk 24 · n 1530 · Phase 3 · secondary NCT01507831
  • -62.8% vs 0.7% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -57.8% vs 3.5% 150 mg Q2W · wk 24 · n 1278 · Phase 3 · secondary NCT01507831
  • -63.3% vs 1.5% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -64.2% vs 1.4% 150 mg Q2W · wk 12 · n 1523 · Phase 3 · secondary NCT01507831
  • -56.8% vs 4.4% 150 mg Q2W · wk 52 · n 1530 · Phase 3 · secondary NCT01507831
  • -59.9% vs 4.6% 150 mg Q2W · wk 52 · n 1523 · Phase 3 · secondary NCT01507831
  • -52.4% vs 3.6% 150 mg Q2W · wk 78 · n 1530 · Phase 3 · secondary NCT01507831
  • -58% vs 3.9% 150 mg Q2W · wk 78 · n 1523 · Phase 3 · secondary NCT01507831
  • -59.4% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -62.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -58.4% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -55.3% vs 1.1% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -60% vs -0.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT01926782
  • -58% vs 1.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 302 · Phase 3 · secondary NCT01926782
  • -49.4% vs 2.7% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -43.5% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -55.1% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -43.8% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -44.2% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -47.1% vs 9% 75 mg/Up to 150 mg Q2W · wk 52 · n 322 · Phase 3 · secondary NCT01623115
  • -40.3% vs 11.5% 75 mg/Up to 150 mg Q2W · wk 78 · n 322 · Phase 3 · secondary NCT01623115
  • -45.5% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -50.7% vs -0.8% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -43.9% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 321 · Phase 3 · secondary NCT01623115
  • -43.7% vs 14% 75 mg/Up to 150 mg Q2W · wk 78 · n 321 · Phase 3 · secondary NCT01623115
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.3% vs 1.1% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -47.6% vs 1.7% 75/150 mg Q2W · wk 12 · n 204 · Phase 3 · secondary NCT01644175
  • -42.1% vs -3% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42% vs -2.9% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42.5% vs 0.5% 75/150 mg Q2W · wk 52 · n 205 · Phase 3 · secondary NCT01644175
  • -49.3% vs 8.8% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -54.6% vs 5.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -43.4% vs -2.8% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -70.1% vs -2.8% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54.2% vs -3.7% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -3.7% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54% vs -2.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -2.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -41.7% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -44.8% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 57 · Phase 3 · secondary NCT02023879
  • -52.3% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · n 58 · Phase 3 · secondary NCT02023879
  • -55% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · n 57 · Phase 3 · secondary NCT02023879
  • -55.3% vs 5.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -50.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 284 · Phase 3 · secondary NCT02585778
  • -43.3% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 277 · Phase 3 · secondary NCT02585778
  • -63.7% vs 1.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -50.8% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -51.5% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -48.8% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 284 · Phase 3 · secondary NCT02585778
  • -44.8% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 275 · Phase 3 · secondary NCT02585778
  • -48.1% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 52 · n 321 · Phase 3 · secondary NCT01623115
  • -40.9% vs -0.2% 150 mg Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -53.8% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -64.2% vs -2.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -62.5% vs -3.6% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -49.4% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -60.2% vs 6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -49.4% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 49 · Phase 3 · secondary NCT02585778
  • -46.7% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 45 · Phase 3 · secondary NCT02585778
  • -57.9% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -58.4% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -64.8% vs -2.8% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -50.3% vs 8.4% 75 mg/up to 150 mg · wk 52 · n 166 · Phase 3 · secondary NCT01709500
  • -64.6% vs -3.4% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -42.3% vs 4% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -53.7% vs 1.6% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -53.6% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -54.1% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -54.6% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -51.8% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -45.3% vs 1.1% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -53.9% vs -0.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -47.3% vs 1.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -37.9% vs 1.2% 150 Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -52.4% vs -21.8% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -51.2% vs -21.8% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -52.4% vs -22.7% 75 /up to 150 mg Q2W · wk 12 · n 464 · Phase 3 · secondary NCT01644188
  • -49.5% vs -18.3% 75 /up to 150 mg Q2W · wk 52 · n 467 · Phase 3 · secondary NCT01644188
  • -51.8% vs -19.7% 75 /up to 150 mg Q2W · wk 52 · n 464 · Phase 3 · secondary NCT01644188
  • -44.2% vs -15.2% 75 /up to 150 mg Q2W · wk 104 · n 467 · Phase 3 · secondary NCT01644188
  • -48.9% vs -17% 75 /up to 150 mg Q2W · wk 104 · n 464 · Phase 3 · secondary NCT01644188
  • -58.7% vs -21.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -57.1% vs -22.2% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -58.1% vs -22.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 401 · Phase 3 · secondary NCT02715726
  • -48.1% vs -19.6% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -52.2% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -47.3% vs -15.2% 75 mg/ up to 150 mg · wk 24 · n 112 · Phase 3 · secondary NCT01709513
  • -47% vs -15.6% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -51.2% vs -18% 75 mg/ up to 150 mg · wk 12 · n 123 · Phase 3 · secondary NCT01709513
  • -53.5% vs -17% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -41.5% vs -17% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -48.6% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -57.8% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -49.6% vs -22.1% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -32.3% vs -22.1% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -52.6% vs -22.9% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -35.1% vs -22.9% 75 mg/up to 150 mg + 20 mg · wk 12 · n 51 · Phase 3 · secondary NCT01730053
  • -48.4% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -50.5% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -53.7% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 52 · Phase 3 · secondary NCT01730040
  • -50.9% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -66.2% vs -51.2% wk 4 · n 31 · Phase 3 · secondary NCT03415178
  • -73% vs 2% wk 2 · n 10 · Phase 4 · primary NCT02938949
  • -54.2% vs 3% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -49.6% vs 0.6% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -51.4% vs 2.8% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -50.4% vs 2.4% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -46.2% vs 4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -43.3% vs -0.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -41.7% vs -7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -64.5% vs -7.6% wk 12 · n 93 · Phase 4 · secondary NCT02984982
  • -63.9% vs -13.4% wk 36 · n 93 · Phase 4 · secondary NCT02984982
Lerodalcibep
-9.3% vs -11%avs evolocumabwk 24NCT04034485
1 other result
  • -53% vs -45.3% wk 38.5714285714 · Phase 3 · primary NCT05004675

Non-HDL-C, % change

Alirocumab
-51.6% vs 0.7%−52.3 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
87 other results
  • -53.1% vs 0.6% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -53.7% vs 0.9% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -43.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -49.7% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -48.9% vs 0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -52.6% vs 0.2% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -49.9% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -46.5% vs 0.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -42.8% vs 9.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -43.3% vs 9.4% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -38.4% vs 5.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -41.9% vs -6.2% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -41.7% vs -6.1% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -39.1% vs -1.6% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -40.9% vs -0.5% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -41.4% vs -6.9% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -37.4% vs 2.6% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -42.6% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -43.2% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -37.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -44.2% vs 4.8% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -46.7% vs 5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -36.2% vs -4.9% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -4.9% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -35.9% vs -3.5% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -3.5% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -34.9% vs 3% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -45.3% vs 4.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -46.9% vs 5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -45.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -47.2% vs 4.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -50.1% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -54.9% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -56% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -43.4% vs 3% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -47.3% vs 3.9% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -56.3% vs -1.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -35.7% vs 4.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -47.1% vs 2.8% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -41.6% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -37.9% vs 4.1% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -43.6% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -47.2% vs 0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -44.4% vs 0.2% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -45.8% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -37.4% vs 0.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -42.1% vs -19.2% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -43.7% vs -20.2% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -42.6% vs -20.6% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -47% vs -19.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -49.1% vs -20.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -47.4% vs -20.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -40.6% vs -15.1% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -42.5% vs -16.7% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -40.2% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -46.9% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -41.5% vs -15.8% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -42.7% vs -11.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -31.4% vs -11.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -45.7% vs -14.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -35.6% vs -14.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -36.7% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -47.6% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -40.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -50.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -41.2% vs -18% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -29.8% vs -18% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -40.6% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -42.3% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -37.3% vs -4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · primary NCT02642159
  • -37% vs 2.5% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.6% vs 1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -41.1% vs 1.7% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -44% vs 2.2% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.4% vs 0.7% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -35.5% vs -9.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -54.5% vs -14.1% wk 36 · n 93 · Phase 4 · secondary NCT02984982
Lerodalcibep
—Not posted · NCT04790513

ApoB, % change

Alirocumab
-52.8% vs 1.2%−54 vs placebo150 mg Q2W · wk 24 · n 1468NCT01507831
86 other results
  • -54.3% vs 1.2% 150 mg Q2W · wk 24 · n 1444 · Phase 3 · secondary NCT01507831
  • -55.5% vs 0.5% 150 mg Q2W · wk 12 · n 1468 · Phase 3 · secondary NCT01507831
  • -40.2% vs -0.7% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01926782
  • -45.1% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 292 · Phase 3 · secondary NCT01926782
  • -44.8% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -47.2% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 286 · Phase 3 · secondary NCT01926782
  • -46.4% vs -2.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 138 · Phase 3 · secondary NCT01926782
  • -41.2% vs 3.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 292 · Phase 3 · secondary NCT01926782
  • -41.1% vs 4.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 309 · Phase 3 · secondary NCT01623115
  • -41.4% vs 4.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01623115
  • -34.5% vs 3.1% 75 mg/Up to 150 mg Q2W · wk 12 · n 309 · Phase 3 · secondary NCT01623115
  • -39% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -38.9% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -36.7% vs -0.9% 75/150 mg Q2W · wk 24 · n 185 · Phase 3 · secondary NCT01644175
  • -37.9% vs -0.4% 75/150 mg Q2W · wk 24 · n 181 · Phase 3 · secondary NCT01644175
  • -39.2% vs -9% 150 mg Q2W · wk 12 · n 69 · Phase 3 · secondary NCT01617655
  • -34.8% vs 3.4% 75/150 mg Q2W · wk 12 · n 185 · Phase 3 · secondary NCT01644175
  • -42.8% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 163 · Phase 3 · secondary NCT01709500
  • -43.2% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 162 · Phase 3 · secondary NCT01709500
  • -33.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 279 · Phase 3 · secondary NCT02585778
  • -38.9% vs 7.5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -40.9% vs 7.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 54 · Phase 3 · secondary NCT02023879
  • -32.2% vs -6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -57.9% vs -6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.8% vs -4.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -58% vs -4.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.3% vs 7% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -39.7% vs 7.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -41.2% vs 7.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -39.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -42.3% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 96 · Phase 3 · secondary NCT02289963
  • -45.4% vs 3.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 95 · Phase 3 · secondary NCT02289963
  • -55% vs -1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT02107898
  • -55.9% vs -2.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 140 · Phase 3 · secondary NCT02107898
  • -38.4% vs 7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 112 · Phase 3 · secondary NCT02023879
  • -40.9% vs 5.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 96 · Phase 3 · secondary NCT02289963
  • -54.6% vs -3.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT02107898
  • -33.8% vs 1.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -42.8% vs 1.2% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -36.7% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -35.4% vs -0.9% 75 mg/up to 150 mg · wk 12 · n 163 · Phase 3 · secondary NCT01709500
  • -39% vs -0.7% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 34 · Phase 3 · secondary NCT01926782
  • -42% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -38.3% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 74 · Phase 3 · secondary NCT01926782
  • -40.8% vs -2.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 34 · Phase 3 · secondary NCT01926782
  • -33% vs 3.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -40.7% vs -18.3% 75 /up to 150 mg Q2W · wk 24 · n 452 · Phase 3 · secondary NCT01644188
  • -42.1% vs -19.1% 75 /up to 150 mg Q2W · wk 24 · n 442 · Phase 3 · secondary NCT01644188
  • -39.7% vs -17.2% 75 /up to 150 mg Q2W · wk 12 · n 452 · Phase 3 · secondary NCT01644188
  • -43.5% vs -16.2% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 398 · Phase 3 · secondary NCT02715726
  • -45.2% vs -17.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 392 · Phase 3 · secondary NCT02715726
  • -43% vs -16.5% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 398 · Phase 3 · secondary NCT02715726
  • -36.7% vs -11% 75/Up to 150 mg Q2W · wk 24 · n 48 · Phase 3 · secondary NCT01644474
  • -37.3% vs -11.7% 75/Up to 150 mg Q2W · wk 12 · n 48 · Phase 3 · secondary NCT01644474
  • -36.3% vs -11.2% 75 mg/ up to 150 mg · wk 24 · n 122 · Phase 3 · secondary NCT01709513
  • -42.6% vs -14.4% 75 mg/ up to 150 mg · wk 24 · n 109 · Phase 3 · secondary NCT01709513
  • -36.1% vs -11.6% 75 mg/ up to 150 mg · wk 12 · n 122 · Phase 3 · secondary NCT01709513
  • -36.5% vs -9.8% 75 mg/up to 150 mg + 10 mg · wk 24 · n 44 · Phase 3 · secondary NCT01730053
  • -28.3% vs -9.8% 75 mg/up to 150 mg + 20 mg · wk 24 · n 49 · Phase 3 · secondary NCT01730053
  • -39.5% vs -12.7% 75 mg/up to 150 mg + 10 mg · wk 24 · n 43 · Phase 3 · secondary NCT01730053
  • -30.4% vs -12.7% 75 mg/up to 150 mg + 20 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -33.7% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730040
  • -41.9% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 42 · Phase 3 · secondary NCT01730040
  • -37.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 50 · Phase 3 · secondary NCT01730040
  • -42.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 41 · Phase 3 · secondary NCT01730040
  • -36.1% vs -13.7% 75 mg/up to 150 mg + 10 mg · wk 12 · n 44 · Phase 3 · secondary NCT01730053
  • -29% vs -13.7% 75 mg/up to 150 mg + 20 mg · wk 12 · n 49 · Phase 3 · secondary NCT01730053
  • -38.4% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730040
  • -36.2% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 42 · Phase 3 · secondary NCT01730040
  • -36.4% vs 1.4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -39.1% vs 0.2% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -39% vs 1.1% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.9% vs 2.1% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -36.7% vs 0.8% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -33.8% vs -1.6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.1% vs -16.6% wk 36 · n 92 · Phase 4 · secondary NCT02984982
Lerodalcibep
—Not posted · NCT04790513

Lp(a), % change

Alirocumab
-29.3% vs -3.7%−25.6 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
64 other results
  • -28.2% vs -3.1% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -21.3% vs 6.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -19.3% vs 9.8% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -28.9% vs -5.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -19.6% vs 7% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -23.5% vs -8.7% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -20.5% vs -5.9% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -23.2% vs -1.5% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -19.7% vs 0% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -25.2% vs -7.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -15.5% vs 4.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -31.7% vs 1.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -49.6% vs 1.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -5.7% vs 2.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -30.3% vs -10% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -21.8% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -19% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -21.2% vs -3.9% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -24.7% vs -5.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -6.1% vs -1.2% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -18.1% vs -4% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -14% vs 6.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -16.9% vs 9.8% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -23% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -35.9% vs -2.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -39.5% vs 2.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -26.9% vs -5.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -12.4% vs 7% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -16.5% vs 2.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -33.6% vs -1.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -41.9% vs -0.5% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16.0% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -27.8% vs -6.1% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -22.1% vs 1.1% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -30.3% vs 4.0% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -30.1% vs 6.3% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -16.7% vs -12.3% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -17.2% vs -14.2% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -25.9% vs -7.3% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -21.7% vs -4.5% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -27.9% vs -5.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -22.7% vs -5.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -23.6% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -30.8% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -20.7% vs 3.5% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -16% vs 3.5% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -24% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -27.9% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -17.7% vs 4.8% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -25.1% vs -1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -24.3% vs -1.4% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -24.7% vs -0.5% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -22.4% vs -3.3% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -23.7% vs 3.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.8% vs -17.2% wk 36 · n 92 · Phase 4 · secondary NCT02984982
Lerodalcibep
—Not posted · NCT04790513

3-point MACE (% with event)

Alirocumab
—Not posted · NCT04790513
Lerodalcibep
—Not posted · NCT04790513
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Alirocumab: 6 of 6 rows · Lerodalcibep: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlirocumab
Rows use multiple source trials
Lerodalcibep
Rows use multiple source trials
LDL-C
percent change · % of baseline
No placebo or comparator arm
-47% (n=47) @ 24wk75 mg Q2W/Up to 150 mg Q2Wa,b,c,d
NCT02642159 · Phase 4 · registry result, not featured evidence
show 1 more dose
-44.3% (n=47) @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
58.61% @ 24wka,b,c,d
NCT04797104 · Phase 3 · sponsor-reported, not registry data
show 1 more dose
65%
NCT04797104 · Phase 3 · sponsor-reported, not registry data
LDL-C
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
-55.67% (n=42) @ 52wke,d
NCT01576484 · Phase 2 · registry result, not featured evidence
64.1% (n=32) @ 52wke,d
NCT03847974 · Phase 2 · registry result, not featured evidence
Dropout rate
28.3%150 mg Q2Wf
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 84 more results
40.3%150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—150 Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—75 /up to 150 mg Q2W
NCT01644175 · Phase 3
25.4%75/150 mg Q2W
NCT01644175 · Phase 3
—75/Up to 150 mg Q2W
NCT01623115 · Phase 3
23.8%75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
n/a: no completion milestone75 mg/up to 150 mg
NCT01709500 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
12.8%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
28.1%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
16.7%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
21.6%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
9.8%150 mg Q2W
NCT02326220 · Phase 3
25.5%75 /up to 150 mg Q2W
NCT01644188 · Phase 3
—75/Up to 150 mg Q2W
NCT01644188 · Phase 3
15.4%75/Up to 150 mg Q2W
NCT01644474 · Phase 3
—75/Up150 mg Q2W
NCT01644474 · Phase 3
0%150 mg SC Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
8.2%Q2W
NCT03510884 · Phase 3
5.8%Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
0%Q2W
NCT03510884 · Phase 3
3.7%Q4W
NCT03510884 · Phase 3
22%75 mg Q2W/Up to 150 mg Q2W
NCT01663402 · Phase 3
—Alirocumab
NCT01663402 · Phase 3
15.5%75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
0%
NCT02938949 · Phase 4 · registry result, not featured evidence
9.6%
NCT02984982 · Phase 4 · registry result, not featured evidence
11.2%75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
12%
NCT02476006 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Parallel
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Single-a
NCT03415178 · Phase 3 · registry result, not featured evidence
5.7%New Auto-injector Device (SYDNEY)
NCT03415178 · Phase 3 · registry result, not featured evidence
6.6%75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/up150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
3.8%150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
0%150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
8.7%75 or 150 mg Q2W
NCT01954394 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
15.3%150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
23.8%75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
9.6%75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
10.3%75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
—75 mg/ Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
8.3%75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
22.4%75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
24.1%75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
19.3%75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
19.1%75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
0%300 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm/ApoB LOFm: Alirocumab F
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm: Alirocumab From Day 1
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm: Alirocumab From Day 15
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
41.3%
NCT01576484 · Phase 2 · registry result, not featured evidence
18.8%g
NCT03847974 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
7.3%150 mg Q2Wf
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 84 more results
4.2%150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—150 Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—75 /up to 150 mg Q2W
NCT01644175 · Phase 3
6.2%75/150 mg Q2W
NCT01644175 · Phase 3
—75/Up to 150 mg Q2W
NCT01623115 · Phase 3
4%75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
3%75 mg/up to 150 mg
NCT01709500 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
5.4%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
9.6%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
5.1%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
8.1%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
4.9%150 mg Q2W
NCT02326220 · Phase 3
9.2%75 /up to 150 mg Q2W
NCT01644188 · Phase 3
—75/Up to 150 mg Q2W
NCT01644188 · Phase 3
9.6%75/Up to 150 mg Q2W
NCT01644474 · Phase 3
—75/Up150 mg Q2W
NCT01644474 · Phase 3
—150 mg SC Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
0%Q2W
NCT03510884 · Phase 3
3.8%Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
0%Q2W
NCT03510884 · Phase 3
0%Q4W
NCT03510884 · Phase 3
3.8%75 mg Q2W/Up to 150 mg Q2W
NCT01663402 · Phase 3
—Alirocumab
NCT01663402 · Phase 3
6.2%75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
—
NCT02938949 · Phase 4 · registry result, not featured evidence
4.8%
NCT02984982 · Phase 4 · registry result, not featured evidence
3.6%75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
4.1%
NCT02476006 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Parallel
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Single-a
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-injector Device (SYDNEY)
NCT03415178 · Phase 3 · registry result, not featured evidence
1.5%75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/up150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
1.9%150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
0%150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
3.5%75 or 150 mg Q2W
NCT01954394 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
8.5%150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
18.3%75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
4.9%75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
2.1%75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
—75 mg/ Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
4.9%75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
6.1%75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
3.7%75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
8.8%75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
4.3%75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
—300 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—PCSK9 GOFm/ApoB LOFm: Alirocumab F
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9 GOFm: Alirocumab From Day 1
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9 GOFm: Alirocumab From Day 15
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
2.2%
NCT01576484 · Phase 2 · registry result, not featured evidence
3.1%g
NCT03847974 · Phase 2 · registry result, not featured evidence
Serious AEs
18.7%150 mg Q2Wf
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 84 more results
—150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
13.9%150 Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
12.6%75 /up to 150 mg Q2W
NCT01644175 · Phase 3
—75/150 mg Q2W
NCT01644175 · Phase 3
13.7%75/Up to 150 mg Q2W
NCT01623115 · Phase 3
—75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
6%75 mg/up to 150 mg
NCT01709500 · Phase 3
11.6%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
11.3%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
9.8%150 mg Q2W
NCT02326220 · Phase 3
3.4%150 mg Q2W
NCT02326220 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
—75 /up to 150 mg Q2W
NCT01644188 · Phase 3
25.9%75/Up to 150 mg Q2W
NCT01644188 · Phase 3
—75/Up to 150 mg Q2W
NCT01644474 · Phase 3
1.9%75/Up150 mg Q2W
NCT01644474 · Phase 3
—150 mg SC Q2W
NCT03156621 · Phase 3
0%150 Q2W
NCT03156621 · Phase 3
2.2%150 Q2W
NCT03156621 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
8.2%Q2W
NCT03510884 · Phase 3
3.8%Q4W
NCT03510884 · Phase 3
8.7%Q2W
NCT03510884 · Phase 3
6.1%Q4W
NCT03510884 · Phase 3
0%Q2W
NCT03510884 · Phase 3
8%Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—75 mg Q2W/Up to 150 mg Q2W
NCT01663402 · Phase 3
23.3%Alirocumab
NCT01663402 · Phase 3
17.4%75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
40%
NCT02938949 · Phase 4 · registry result, not featured evidence
18.4%
NCT02984982 · Phase 4 · registry result, not featured evidence
9.5%75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
16.2%
NCT02476006 · Phase 3 · registry result, not featured evidence
3%New Auto-Injector Device (Parallel
NCT03415178 · Phase 3 · registry result, not featured evidence
3%New Auto-Injector Device (Single-a
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-injector Device (SYDNEY)
NCT03415178 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
10.1%75 mg Q2W/up150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
—150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
3.8%150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
1.9%150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
7.6%150 mg Q4W/Up Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
22%75 or 150 mg Q2W
NCT01954394 · Phase 3 · registry result, not featured evidence
29.2%150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
26.4%150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
29.4%150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
12.1%150 mg Q4W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
6.1%75 mg Q2W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
9.5%75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
9%75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
17.5%75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
7%75 mg/ Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
—75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
4.1%75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
7.4%75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
5.3%75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
2.1%75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
0%300 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm/ApoB LOFm: Alirocumab F
NCT01604824 · Phase 2 · registry result, not featured evidence
16.7%PCSK9 GOFm: Alirocumab From Day 1
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm: Alirocumab From Day 15
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
17.4%
NCT01576484 · Phase 2 · registry result, not featured evidence
9.4%g
NCT03847974 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
150 mg Q2Wf
nasopharyngitis 13.5% (placebo 13.1%)
upper respiratory tract infection 7.4% (placebo 8.6%)
injection site reaction 5.9% (placebo 4.2%)
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 60 more results
150 Q2W
nasopharyngitis 13.9% (placebo 11.4%)
influenza 12.5% (placebo 2.9%)
injection site reaction 8.3% (placebo 5.7%)
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
75 /up to 150 mg Q2W
upper respiratory tract infection 7.7% (placebo 10.3%)
nasopharyngitis 7.2% (placebo 4.7%)
urinary tract infection 6.3% (placebo 3.7%)
NCT01644175 · Phase 3
75/Up to 150 mg Q2W
injection site reaction 12.4% (placebo 11%)
nasopharyngitis 11.2% (placebo 7.4%)
upper respiratory tract infection 6.8% (placebo 8.6%)
NCT01623115 · Phase 3
75 mg/up to 150 mg
influenza 14.4% (placebo 7.4%)
injection site reaction 10.8% (placebo 7.4%)
nasopharyngitis 10.8% (placebo 19.8%)
NCT01709500 · Phase 3
300 mg Q4W/Up 150 mg Q2W
injection site reaction 16.2% (placebo 7%)
upper respiratory tract infection 9% (placebo 7.9%)
nasopharyngitis 8.5% (placebo 7.9%)
NCT01926782 · Phase 3
75 mg Q2W/Up 150 mg Q2W
injection site reaction 8.7% (placebo 7%)
nasopharyngitis 8.7% (placebo 7.9%)
upper respiratory tract infection 7% (placebo 7.9%)
NCT01926782 · Phase 3
150 mg Q2W
fatigue 14.6% (placebo 9.5%)
myalgia 12.2% (placebo 4.8%)
diarrhoea 9.8% (placebo 0%)
NCT02326220 · Phase 3
150 mg Q2W
anaemia 6.9% (placebo 0%)
nasopharyngitis 3.4% (placebo 9.5%)
arthralgia 0% (placebo 9.5%)
NCT02326220 · Phase 3
75/Up to 150 mg Q2W
accidental overdose 9.8%
upper respiratory tract infection 8.8%
hypertension 6.5%
NCT01644188 · Phase 3
75/Up150 mg Q2W
nasopharyngitis 23.1%
diarrhoea 11.5%
influenza 11.5%
NCT01644474 · Phase 3
150 Q2W
diarrhoea 6.7% (placebo 0%)
headache 4.4% (placebo 8.3%)
nasopharyngitis 4.4% (placebo 0%)
NCT03156621 · Phase 3
150 Q2W
nasopharyngitis 6.7% (placebo 0%)
diarrhoea 2.2% (placebo 0%)
headache 2.2% (placebo 8.3%)
NCT03156621 · Phase 3
Q2W
nasopharyngitis 14.3% (placebo 8%)
headache 6.1% (placebo 8%)
injection site reaction 6.1% (placebo 0%)
NCT03510884 · Phase 3
Q4W
headache 7.7% (placebo 8%)
upper respiratory tract infection 5.8% (placebo 12%)
injection site reaction 3.8% (placebo 0%)
NCT03510884 · Phase 3
Q2W
headache 10.9% (placebo 8%)
oropharyngeal pain 8.7% (placebo 0%)
injection site reaction 6.5% (placebo 0%)
NCT03510884 · Phase 3
Q4W
headache 14.3% (placebo 8%)
covid-19 8.2% (placebo 0%)
nasopharyngitis 6.1% (placebo 8%)
NCT03510884 · Phase 3
Q2W
low density lipoprotein decreased 8% (placebo 0%)
nasopharyngitis 8% (placebo 8%)
nausea 8% (placebo 0%)
NCT03510884 · Phase 3
Q4W
headache 16% (placebo 8%)
covid-19 4% (placebo 0%)
injection site reaction 4% (placebo 0%)
NCT03510884 · Phase 3
nasopharyngitis 6% (placebo 5.6%)
hypertension 5.7% (placebo 6.1%)
myalgia 5.5% (placebo 5.3%)
NCT01663402 · Phase 3
75 Q2W/Up150 Q2W
nasopharyngitis 7.5% (placebo 8.2%)
headache 6.5% (placebo 7.8%)
hypertension 5.9% (placebo 6.7%)
NCT02957682 · Phase 4 · registry result, not featured evidence
nasopharyngitis 26.2%
injection site reaction 6.8%
back pain 5.8%
NCT02984982 · Phase 4 · registry result, not featured evidence
75 mg Q2W/Up to 150 mg Q2W
urinary tract infection 5.5%
diarrhoea 5.1%
arthralgia 2.2%
NCT02642159 · Phase 4 · registry result, not featured evidence
150 mg Q2W
nasopharyngitis 22.2%
alanine aminotransferase increased 11.1%
aortic valve incompetence 11.1%
NCT03510715 · Phase 3 · registry result, not featured evidence
75 mg Q2W/up to 150 mg Q2W
aortic valve incompetence 22.2%
headache 22.2%
influenza 22.2%
NCT03510715 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.8%
myalgia 7.1%
headache 6.1%
NCT02476006 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 9.1%
arthralgia 6.1%
contusion 3%
NCT03415178 · Phase 3 · registry result, not featured evidence
urinary tract infection 6.1%
arthralgia 4.5%
contusion 1.5%
NCT03415178 · Phase 3 · registry result, not featured evidence
75 mg Q2W/up150 mg Q2W
upper respiratory tract infection 13.3%
accidental overdose 6.7%
NCT02715726 · Phase 3 · registry result, not featured evidence
150 mg Q2W
viral upper respiratory tract infection 15.1% (placebo 16.1%)
non-cardiac chest pain 7.5% (placebo 1.8%)
back pain 1.9% (placebo 0%)
NCT02584504 · Phase 3 · registry result, not featured evidence
150 mg Q4W
viral upper respiratory tract infection 14.8% (placebo 16.1%)
pharyngitis 5.6% (placebo 0%)
back pain 0% (placebo 0%)
NCT02584504 · Phase 3 · registry result, not featured evidence
150 mg Q4W/Up Q2W
viral upper respiratory tract infection 34.2% (placebo 16.1%)
fall 7% (placebo 5.4%)
back pain 5.1% (placebo 0%)
NCT02584504 · Phase 3 · registry result, not featured evidence
75 or 150 mg Q2W
viral upper respiratory tract infection 14.2%
upper respiratory tract infection 10.8%
influenza 9.3%
NCT01954394 · Phase 3 · registry result, not featured evidence
150 mg Q4W
viral upper respiratory tract infection 18.8% (placebo 5.2%)
back pain 14.6% (placebo 0%)
injection site reaction 14.6% (placebo 0%)
NCT02023879 · Phase 3 · registry result, not featured evidence
150 mg Q4W
viral upper respiratory tract infection 15.1% (placebo 5.2%)
fall 13.2% (placebo 1.7%)
diarrhoea 10.4% (placebo 3.4%)
NCT02023879 · Phase 3 · registry result, not featured evidence
150 mg Q4W
cough 17.6% (placebo 0%)
arthralgia 15.7% (placebo 6.9%)
osteoarthritis 15.7% (placebo 3.4%)
NCT02023879 · Phase 3 · registry result, not featured evidence
150 mg Q4W/Up150 mg Q2W
injection site reaction 13.8% (placebo 0%)
arthralgia 12.1% (placebo 6.9%)
headache 8.6% (placebo 6.9%)
NCT02023879 · Phase 3 · registry result, not featured evidence
75 mg Q2W/Up150 mg Q2W
headache 8.7% (placebo 6.9%)
viral upper respiratory tract infection 8.7% (placebo 5.2%)
muscle spasms 7.8% (placebo 0%)
NCT02023879 · Phase 3 · registry result, not featured evidence
75 mg/ up to 150 mg
myalgia 24.6%
nasopharyngitis 6.3%
upper respiratory tract infection 5.6%
NCT01709513 · Phase 3 · registry result, not featured evidence
75 mg Q2W/Up to 150 mg Q2W
nasopharyngitis 4.9% (placebo 5.3%)
NCT02585778 · Phase 3 · registry result, not featured evidence
75 mg Q2W/Up to 150 mg Q2W
dizziness 6.2% (placebo 2.9%)
nasopharyngitis 6.2% (placebo 3.9%)
diarrhoea 5.2% (placebo 1%)
NCT02289963 · Phase 3 · registry result, not featured evidence
75 mg/ Up to 150 mg Q2W
nasopharyngitis 45.5% (placebo 36.1%)
back pain 12.6% (placebo 5.6%)
injection site reaction 12.6% (placebo 4.2%)
NCT02107898 · Phase 3 · registry result, not featured evidence
75 mg/up to 150 mg + 10 mg
arthralgia 8.2%
nausea 6.1%
nasopharyngitis 4.1%
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
75 mg/up to 150 mg + 20 mg
myalgia 7.4%
upper respiratory tract infection 7.4%
injection site reaction 5.6%
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
75 mg/up to 150 mg + Atorvastatin 20 mg
muscle spasms 7%
back pain 5.3%
arthralgia 3.5%
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
75 mg/up to 150 mg + Atorvastatin 40 mg
back pain 8.5%
nasopharyngitis 8.5%
accidental overdose 6.4%
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
300 mg Q4W
acne 20%
diarrhoea 20%
influenza like illness 20%
NCT02890992 · Phase 2 · registry result, not featured evidence
150 mg Q4W
nasopharyngitis 20%
pyogenic granuloma 20%
upper respiratory tract infection 20%
NCT02890992 · Phase 2 · registry result, not featured evidence
150 mg Q4W
abdominal discomfort 16.7%
diarrhoea 16.7%
epistaxis 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
75 mg Q2W
ligament sprain 11.1%
nasopharyngitis 11.1%
abdominal pain 5.6%
NCT02890992 · Phase 2 · registry result, not featured evidence
75 mg Q2W
animal scratch 16.7%
arthropod bite 16.7%
blood follicle stimulating hormone decreased 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
75 mg Q4W
abdominal pain 16.7%
asthma 16.7%
depressed mood 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
50 mg Q2W
diarrhoea 33.3%
nasopharyngitis 33.3%
alcohol abuse 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
40 mg Q2W
gastroenteritis viral 30%
ear infection 10%
headache 10%
NCT02890992 · Phase 2 · registry result, not featured evidence
40 mg Q2W
pharyngitis 25%
abdominal discomfort 0%
abdominal pain 0%
NCT02890992 · Phase 2 · registry result, not featured evidence
30 mg Q2W
ear infection 25%
epistaxis 25%
fall 25%
NCT02890992 · Phase 2 · registry result, not featured evidence
viral upper respiratory tract infection 40%
acne 20%
blood bilirubin increased 20%
NCT01604824 · Phase 2 · registry result, not featured evidence
gastroenteritis 33.3%
viral upper respiratory tract infection 33.3%
abdominal discomfort 16.7%
NCT01604824 · Phase 2 · registry result, not featured evidence
headache 28.6%
acne 14.3%
angina pectoris 14.3%
NCT01604824 · Phase 2 · registry result, not featured evidence
abdominal discomfort 20%
abdominal distension 20%
acne 20%
NCT01604824 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 28.3%
nasopharyngitis 23.9%
bronchitis 21.7%
NCT01576484 · Phase 2 · registry result, not featured evidence
g
other adverse event 87.5%
other (not including serious) adverse events were not monitored/assessed using specific adverse even 9.4%
NCT03847974 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 4 versus Phase 3.
  3. cPopulation context differs: registered conditions differ.
  4. dTreatment context has not been resolved for both arms.
  5. ePopulation comparability has not been reviewed for both studies.
  6. fPopulation comparability has not been reviewed for 82 of these studies.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alirocumab

Apo B -40.2% (n=138) vs -0.7% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 86 more results
-45.1% (n=292) vs 3.1% (n=146) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-44.8% (n=141) vs -0.3% (n=70) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-47.2% (n=286) vs 3.1% (n=142) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-46.4% (n=138) vs -2.3% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-41.2% (n=292) vs 3.6% (n=146) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-52.8% (n=1468) vs 1.2% (n=753) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-54.3% (n=1444) vs 1.2% (n=743) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-55.5% (n=1468) vs 0.5% (n=753) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-39% (n=69) vs -8.7% (n=34) placebo @ 24wk150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-38.9% (n=69) vs -8.7% (n=34) placebo @ 24wk150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-39.2% (n=69) vs -9% (n=34) placebo @ 12wk150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-36.7% (n=185) vs -0.9% (n=96) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
-37.9% (n=181) vs -0.4% (n=93) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
-34.8% (n=185) vs 3.4% (n=96) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
-42.8% (n=41) vs 1.2% (n=21) placebo @ 6wk150 mg Q2W
NCT02326220 · Phase 3
-33.8% (n=41) vs 1.7% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
-40.7% (n=452) vs -18.3% (n=228) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-42.1% (n=442) vs -19.1% (n=221) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-39.7% (n=452) vs -17.2% (n=228) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-36.7% (n=48) vs -11% (n=46) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-37.3% (n=48) vs -11.7% (n=46) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-22.5% (n=45) vs 7.2% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-22.5% (n=45) vs 7.2% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-32.2% (n=54) vs -6% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
-57.9% (n=53) vs -6% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
-31.8% (n=54) vs -4.6% (n=55) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
-58% (n=53) vs -4.6% (n=55) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
-38.9% (n=58) vs 7.5% (n=56) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-40.9% (n=54) vs 7.7% (n=54) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-31.3% (n=58) vs 7% (n=56) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-41.1% (n=309) vs 4.7% (n=160) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-41.4% (n=308) vs 4.5% (n=159) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-34.5% (n=309) vs 3.1% (n=160) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-42.8% (n=163) vs -3.5% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-43.2% (n=162) vs -3.5% (n=80) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-35.4% (n=163) vs -0.9% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-39% (n=34) vs -0.7% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-36.7% (n=75) vs 3.1% (n=146) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-42% (n=37) vs -0.3% (n=70) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-38.3% (n=74) vs 3.1% (n=142) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-40.8% (n=34) vs -2.3% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-33% (n=75) vs 3.6% (n=146) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-33.8% (n=273) vs -1.6% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
-43.5% (n=398) vs -16.2% (n=203) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-45.2% (n=392) vs -17.4% (n=197) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-43% (n=398) vs -16.5% (n=203) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-39.7% (n=112) vs 7.5% (n=56) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-41.2% (n=112) vs 7.7% (n=54) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-38.4% (n=112) vs 7% (n=56) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-36.3% (n=122) vs -11.2% (n=116) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-42.6% (n=109) vs -14.4% (n=95) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-36.1% (n=122) vs -11.6% (n=116) Ezetimibe @ 12wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-39.4% (n=47) vs -0.4% (n=22) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-33.4% (n=279) vs -0.4% (n=22) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-42.3% (n=96) vs 4.1% (n=100) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-45.4% (n=95) vs 3.8% (n=99) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-40.9% (n=96) vs 5.2% (n=100) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-55% (n=141) vs -1.6% (n=71) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-55.9% (n=140) vs -2.1% (n=70) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-54.6% (n=141) vs -3.3% (n=71) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-36.5% (n=44) vs -7.3% (n=44) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-28.3% (n=49) vs -7.3% (n=44) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-39.5% (n=43) vs -8.8% (n=44) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-30.4% (n=48) vs -8.8% (n=44) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-36.1% (n=44) vs -8.1% (n=44) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-29% (n=49) vs -8.1% (n=44) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-33.7% (n=53) vs -4.4% (n=51) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-41.9% (n=42) vs -4.4% (n=51) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-37.7% (n=50) vs -5.1% (n=48) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-42.7% (n=41) vs -5.1% (n=48) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-38.4% (n=53) vs -6.9% (n=51) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-36.2% (n=42) vs -6.9% (n=51) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-27.4% (n=47) vs 10.4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-34.3% (n=49) vs 10.4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-30% (n=47) vs 8.9% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-31.7% (n=49) vs 8.9% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-30% (n=47) vs 8.9% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-31.7% (n=49) vs 8.9% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-27.4% (n=47) vs 10.4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-34.3% (n=49) vs 10.4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-36.7% (n=1058) vs 0.8% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-40.9% (n=1058) vs 2.1% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-39% (n=1058) vs 1.1% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-39.1% (n=1058) vs 0.2% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-36.4% (n=1058) vs 1.4% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-55.13% (n=92) vs -16.61% (n=88) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
Non-HDL-C -43.3% (n=144) vs -0.3% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 87 more results
-49.7% (n=308) vs 0.3% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-48.9% (n=141) vs 0.1% (n=70) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-52.6% (n=302) vs 0.2% (n=151) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-49.9% (n=144) vs -0.4% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-46.5% (n=308) vs 0.6% (n=156) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-51.6% (n=1530) vs 0.7% (n=780) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-53.1% (n=1523) vs 0.6% (n=777) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-53.7% (n=1530) vs 0.9% (n=780) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-41.9% (n=71) vs -6.2% (n=35) placebo @ 24wk150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-41.7% (n=71) vs -6.1% (n=35) placebo @ 24wk150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-41.4% (n=71) vs -6.9% (n=35) placebo @ 12wk150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-39.1% (n=205) vs -1.6% (n=106) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
-40.9% (n=204) vs -0.5% (n=105) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
-37.4% (n=205) vs 2.6% (n=106) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
-47.1% (n=41) vs 2.8% (n=21) placebo @ 6wk150 mg Q2W
NCT02326220 · Phase 3
-35.7% (n=41) vs 4.7% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
-42.1% (n=467) vs -19.2% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-43.7% (n=464) vs -20.2% (n=235) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-42.6% (n=467) vs -20.6% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-40.6% (n=52) vs -15.1% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-42.5% (n=52) vs -16.7% (n=51) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-24.8% (n=45) vs 8% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-24.8% (n=45) vs 8% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-36.2% (n=54) vs -4.9% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
-61.1% (n=53) vs -4.9% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
-35.9% (n=54) vs -3.5% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
-61.1% (n=53) vs -3.5% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
-44.2% (n=58) vs 4.8% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-46.7% (n=57) vs 5% (n=56) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-34.9% (n=58) vs 3% (n=57) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-42.8% (n=322) vs 9.6% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-43.3% (n=321) vs 9.4% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-38.4% (n=322) vs 5.3% (n=163) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-42.6% (n=166) vs 3.1% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-43.2% (n=166) vs 3.1% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-37.9% (n=166) vs 4.1% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-43.6% (n=37) vs -0.3% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-41.6% (n=76) vs 0.3% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-47.2% (n=37) vs 0.1% (n=70) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-44.4% (n=75) vs 0.2% (n=151) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-45.8% (n=37) vs -0.4% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-37.4% (n=76) vs 0.6% (n=156) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-37.3% (n=273) vs -4.7% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
-35.5% (n=273) vs -9.4% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
-47% (n=403) vs -19.4% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-49.1% (n=401) vs -20.4% (n=204) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-47.4% (n=403) vs -20.7% (n=208) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-45.3% (n=115) vs 4.8% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-46.9% (n=115) vs 5% (n=56) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-43.4% (n=115) vs 3% (n=57) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-40.2% (n=126) vs -14.6% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-46.9% (n=123) vs -17.1% (n=118) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-41.5% (n=126) vs -15.8% (n=122) Ezetimibe @ 12wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-45.9% (n=49) vs -3.2% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-37.9% (n=287) vs -3.2% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-47.2% (n=97) vs 4.3% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-50.1% (n=97) vs 4.1% (n=100) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-47.3% (n=97) vs 3.9% (n=102) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-54.9% (n=143) vs 2.6% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-56% (n=143) vs 2.6% (n=71) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-56.3% (n=143) vs -1.7% (n=72) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-42.7% (n=48) vs -11.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-31.4% (n=53) vs -11.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-45.7% (n=48) vs -12.9% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-35.6% (n=51) vs -12.9% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-41.2% (n=48) vs -11.7% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-29.8% (n=53) vs -11.7% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-36.7% (n=55) vs -6.3% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-47.6% (n=46) vs -6.3% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-40.5% (n=52) vs -7.5% (n=52) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-50.5% (n=46) vs -7.5% (n=52) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-40.6% (n=55) vs -7.1% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-42.3% (n=46) vs -7.1% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-31% (n=49) vs 9.7% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-35.6% (n=50) vs 9.7% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-33% (n=49) vs 9.8% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-34.7% (n=50) vs 9.8% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-33% (n=49) vs 9.8% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-34.7% (n=50) vs 9.8% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-31% (n=49) vs 9.7% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-35.6% (n=50) vs 9.7% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-40.4% (n=1058) vs 0.7% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-44% (n=1058) vs 2.2% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-41.1% (n=1058) vs 1.7% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-40.6% (n=1058) vs 1.7% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-37% (n=1058) vs 2.5% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-54.5% (n=93) vs -14.06% (n=89) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
Total-C -33.3% (n=144) vs -1.9% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 36 more results
-35.8% (n=308) vs -0.8% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-37.4% (n=144) vs -1% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-32.9% (n=308) vs -0.1% (n=156) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-37.8% (n=1530) vs -0.3% (n=780) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-38.8% (n=1530) vs 0.2% (n=780) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-29.3% (n=467) vs -14.6% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-29.4% (n=467) vs -15.1% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-32.3% (n=58) vs 3% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-24.5% (n=58) vs 1.8% (n=57) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-31.4% (n=322) vs 7.3% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-28.3% (n=322) vs 4.1% (n=163) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-30.6% (n=166) vs 2.1% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-26.6% (n=166) vs 3.4% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-32.5% (n=37) vs -1.9% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-30% (n=76) vs -0.8% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-33.4% (n=37) vs -1% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-26.5% (n=76) vs -0.1% (n=156) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-34% (n=115) vs 3% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-32.6% (n=115) vs 1.8% (n=57) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-31.8% (n=126) vs -10.9% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-39.5% (n=143) vs 2% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-41.1% (n=143) vs -2.1% (n=72) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-28.9% (n=48) vs -8.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-20.6% (n=53) vs -8.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-29% (n=48) vs -8.9% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-19.4% (n=53) vs -8.9% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-27.1% (n=55) vs -4% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-33.6% (n=46) vs -4% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-29% (n=55) vs -6.5% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-29% (n=46) vs -6.5% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-29.6% (n=1058) vs -0.3% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-31.8% (n=1058) vs 1.5% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-29.6% (n=1058) vs 1.1% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-29% (n=1058) vs 1.1% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-26.5% (n=1058) vs 1.8% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-32.7% (n=126) vs -11.6% (n=122) Ezetimibe @ 12wk75/ up to 150
NCT01709513 · Phase 3 · registry result, not featured evidence
LDL-C Goal Attainment 80.7% (n=1530) vs 8.5% (n=780) placebo @ 24wk150 mg Q2W
responder rate · % of participants
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 25 more results
82.8% (n=1523) vs 8.5% (n=777) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
85.2% (n=54) vs 14.3% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
96.2% (n=53) vs 14.3% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
85.2% (n=54) vs 10.8% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
96.2% (n=53) vs 10.8% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
63.9% (n=58) vs 1.8% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
67.7% (n=57) vs 1.8% (n=56) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
72.2% (n=322) vs 2.4% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
73% (n=321) vs 2.4% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
81.4% (n=166) vs 11.3% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
82.1% (n=166) vs 11.6% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
70.3% (n=115) vs 1.8% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
72.7% (n=115) vs 1.8% (n=56) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
41.9% (n=126) vs 4.4% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
51.2% (n=123) vs 5.6% (n=118) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
96.7% (n=143) vs 10.2% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
97.9% (n=143) vs 10.6% (n=71) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
84.9% (n=48) vs 45% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
66.7% (n=53) vs 45% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
86.4% (n=48) vs 47% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
70.4% (n=51) vs 47% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
87.2% (n=55) vs 34.5% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
84.6% (n=46) vs 34.5% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
91.2% (n=52) vs 37.8% (n=52) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
90% (n=46) vs 37.8% (n=52) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
LDL-C Less Than 70 62% (n=144) vs 3.3% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
responder rate · % of participants
NCT01926782 · Phase 3
show 43 more results
80.4% (n=308) vs 10.9% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
70.4% (n=141) vs 2.1% (n=70) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
84.8% (n=302) vs 10.8% (n=151) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
79.3% (n=1530) vs 8% (n=780) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
81.2% (n=1523) vs 8% (n=777) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
75% (n=205) vs 9% (n=106) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
77.5% (n=204) vs 8% (n=105) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
77% (n=467) vs 45.6% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
78.9% (n=464) vs 47.4% (n=235) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
59.4% (n=52) vs 2.4% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
50% (n=58) vs 0% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
50.9% (n=57) vs 0% (n=56) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
59.8% (n=322) vs 0.8% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
60.1% (n=321) vs 0.8% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
68.2% (n=166) vs 1.2% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
68.8% (n=166) vs 1.3% (n=81) placebo @ 52wk75 mg/up to 150 mg
NCT01709500 · Phase 3
57.7% (n=37) vs 3.3% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
74.4% (n=76) vs 10.9% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
61.7% (n=37) vs 2.1% (n=70) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
77.4% (n=75) vs 10.8% (n=151) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
85.1% (n=403) vs 40.5% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
87% (n=401) vs 42.1% (n=204) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
60% (n=115) vs 0% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
61.7% (n=115) vs 0% (n=56) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
32.5% (n=126) vs 0.8% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
39% (n=123) vs 0.8% (n=118) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
70.2% (n=49) vs 5.1% (n=24) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
76.4% (n=284) vs 5.1% (n=24) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
85.8% (n=97) vs 14.2% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
88.8% (n=97) vs 14.1% (n=100) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
77.8% (n=48) vs 31.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
60.1% (n=53) vs 31.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
76.5% (n=48) vs 34.8% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
66.1% (n=51) vs 34.8% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
79.2% (n=55) vs 16% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
77.2% (n=46) vs 16% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
82.3% (n=52) vs 20% (n=52) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
83.7% (n=46) vs 20% (n=52) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
69.4% (n=1058) vs 10.3% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
74.7% (n=1058) vs 8.4% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
71.4% (n=1058) vs 10.7% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
69.7% (n=1058) vs 11.3% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
64.5% (n=1058) vs 10.7% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
Lp(a -21.3% (n=144) vs 6.4% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 64 more results
-19.3% (n=308) vs 9.8% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-28.9% (n=144) vs -5.5% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-19.6% (n=308) vs 7% (n=156) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-29.3% (n=1530) vs -3.7% (n=780) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-28.2% (n=1530) vs -3.1% (n=780) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-23.5% (n=71) vs -8.7% (n=35) placebo @ 24wk150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-23.2% (n=71) vs -1.5% (n=35) placebo @ 12wk150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-20.5% (n=205) vs -5.9% (n=106) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
-19.7% (n=205) vs 0% (n=106) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
-18.1% (n=41) vs -4% (n=21) placebo @ 6wk150 mg Q2W
NCT02326220 · Phase 3
-6.1% (n=41) vs -1.2% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
-27.8% (n=467) vs -6.1% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-22.1% (n=467) vs 1.1% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-16.7% (n=52) vs -12.3% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-17.2% (n=52) vs -14.2% (n=51) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-19.6% (n=45) vs 8.8% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-19.6% (n=45) vs 8.8% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-31.7% (n=54) vs 1.3% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
-49.6% (n=53) vs 1.3% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
-15.5% (n=58) vs 4.1% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-5.7% (n=58) vs 2.2% (n=57) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-25.2% (n=322) vs -7.5% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-21.2% (n=322) vs -3.9% (n=163) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-30.3% (n=166) vs -10% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-24.7% (n=166) vs -5.6% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-14% (n=37) vs 6.4% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-16.9% (n=76) vs 9.8% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-26.9% (n=37) vs -5.5% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-12.4% (n=76) vs 7% (n=156) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-23.7% (n=273) vs 3.7% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
-30.317% (n=403) vs 3.956% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-30.064% (n=403) vs 6.313% (n=208) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-21.8% (n=115) vs 4.1% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-16.5% (n=115) vs 2.2% (n=57) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-25.9% (n=126) vs -7.3% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-21.7% (n=126) vs -4.5% (n=122) Ezetimibe @ 12wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-23% (n=49) vs -4.3% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-19% (n=287) vs -4.3% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-35.862% (n=97) vs -2.251% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-33.601% (n=97) vs -1.676% (n=102) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-39.5% (n=143) vs 2.5% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-41.9% (n=143) vs -0.5% (n=72) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-27.9% (n=48) vs -4% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-22.7% (n=53) vs -4% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-20.7% (n=48) vs -0.7% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-16% (n=53) vs -0.7% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-23.6% (n=55) vs -20.2% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-30.8% (n=46) vs -20.2% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-24% (n=55) vs -11.7% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-27.9% (n=46) vs -11.7% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-14.7% (n=49) vs 0.5% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-22.4% (n=52) vs 0.5% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-12.7% (n=49) vs -7.1% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-16% (n=52) vs -7.1% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-12.746% (n=49) vs -7.099% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-16.042% (n=52) vs -7.099% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-14.748% (n=49) vs 0.492% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-22.418% (n=52) vs 0.492% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-22.4% (n=1058) vs -3.3% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-24.7% (n=1058) vs -0.5% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-24.3% (n=1058) vs -1.4% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-25.1% (n=1058) vs -1.7% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-17.7% (n=1058) vs 4.8% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-55.76% (n=92) vs -17.23% (n=88) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
HDL-C 2.5% (n=144) vs -5.3% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 62 more results
3.6% (n=308) vs -1.5% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
6% (n=144) vs -0.9% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
5.7% (n=308) vs 0.4% (n=156) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
4% (n=1530) vs -0.6% (n=780) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
5.8% (n=1530) vs 0.2% (n=780) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
3.5% (n=205) vs -3.8% (n=106) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
6.7% (n=205) vs -2.4% (n=106) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
9.3% (n=41) vs 4% (n=21) placebo @ 6wk150 mg Q2W
NCT02326220 · Phase 3
10.9% (n=41) vs 2.4% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
8.6% (n=467) vs 0.5% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
8.7% (n=467) vs 2.8% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
6% (n=52) vs 1.6% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
9% (n=52) vs 1.6% (n=51) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
6.3% (n=45) vs 2.7% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
6.3% (n=45) vs 2.7% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
7.7% (n=54) vs 2% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
9.9% (n=53) vs 2% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
7.7% (n=58) vs -2.4% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
8.6% (n=58) vs -0.8% (n=57) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
8.8% (n=322) vs 0.8% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
6.4% (n=322) vs 2.1% (n=163) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
6% (n=166) vs -0.8% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
6% (n=166) vs -0.8% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-0.1% (n=37) vs -5.3% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
6% (n=76) vs -1.5% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
2.5% (n=37) vs -0.9% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
7.6% (n=76) vs 0.4% (n=156) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
14.5% (n=273) vs 8.2% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
8.3% (n=403) vs 6.5% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
7.3% (n=403) vs 6.1% (n=208) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
7.4% (n=115) vs -2.4% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
6.8% (n=115) vs -0.8% (n=57) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
7.7% (n=126) vs 6.8% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
9% (n=126) vs 7.6% (n=122) Ezetimibe @ 12wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
11.2% (n=49) vs 7.3% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
8.1% (n=287) vs 7.3% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
13.8% (n=97) vs 6.2% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
7.1% (n=97) vs 2% (n=102) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
7.9% (n=143) vs 2.1% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
4.7% (n=143) vs -1.8% (n=72) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
9.1% (n=48) vs 1.7% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
7.2% (n=53) vs 1.7% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
5.9% (n=48) vs 0.7% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
8% (n=53) vs 0.7% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
4.8% (n=55) vs 1.9% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
7.7% (n=46) vs 1.9% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
4.1% (n=55) vs -3.2% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
8.5% (n=46) vs -3.2% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
5.6% (n=49) vs -0.8% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
3.4% (n=50) vs -0.8% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
3.5% (n=49) vs -2.2% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
4% (n=50) vs -2.2% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
3.5% (n=49) vs -2.2% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
4% (n=50) vs -2.2% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
5.6% (n=49) vs -0.8% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
3.4% (n=50) vs -0.8% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
5.9% (n=1058) vs 0.6% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
9% (n=1058) vs 3.8% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
9.2% (n=1058) vs 3.8% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
10.3% (n=1058) vs 4.4% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
10.8% (n=1058) vs 5.5% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
21.04% (n=93) vs 12.19% (n=89) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
Fasting Triglycerides -15.6% (n=1530) vs 1.8% (n=780) placebo @ 24wk150 mg Q2W
percent change · % of baseline
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
-16.7% (n=1530) vs 1.2% (n=780) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
Apo A1 5.2% (n=138) vs -1.4% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 59 more results
5.5% (n=292) vs 2.9% (n=146) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
4.6% (n=138) vs -1.8% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
6% (n=292) vs 2.7% (n=146) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
4% (n=1468) vs 1.2% (n=753) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
4.6% (n=1468) vs 0.6% (n=753) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
3.3% (n=185) vs -2.5% (n=96) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
3.8% (n=185) vs -1.8% (n=96) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
4.2% (n=41) vs 0% (n=21) placebo @ 6wk150 mg Q2W
NCT02326220 · Phase 3
7.8% (n=41) vs -0.7% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
5% (n=452) vs -1.3% (n=228) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
1.5% (n=467) vs -2.9% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
4.7% (n=48) vs -0.6% (n=46) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
2.3% (n=48) vs -2.2% (n=46) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
5% (n=45) vs 1.4% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
5% (n=45) vs 1.4% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
6.8% (n=54) vs 2.9% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
9.1% (n=53) vs 2.9% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
10% (n=58) vs 3.4% (n=56) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
7.6% (n=58) vs 2.6% (n=56) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
5% (n=309) vs 0.3% (n=160) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
2.9% (n=309) vs 0.1% (n=160) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
2.8% (n=163) vs -1.6% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
0.4% (n=163) vs -1.9% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
3.1% (n=34) vs -1.4% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
6.5% (n=75) vs 2.9% (n=146) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
2.4% (n=34) vs -1.8% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
6.1% (n=75) vs 2.7% (n=146) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
3.2% (n=398) vs -0.2% (n=203) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
3.7% (n=398) vs 1.1% (n=203) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
8.2% (n=112) vs 3.4% (n=56) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
5.9% (n=112) vs 2.6% (n=56) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
4.8% (n=122) vs 2.9% (n=116) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
5.5% (n=122) vs 3.9% (n=116) Ezetimibe @ 12wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
4.5% (n=96) vs 3.2% (n=100) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
4.5% (n=96) vs 1.5% (n=100) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
1.4% (n=141) vs -2.6% (n=71) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
1.5% (n=141) vs -4.8% (n=71) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
6.7% (n=44) vs 5.4% (n=44) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
6.7% (n=49) vs 5.4% (n=44) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
4.3% (n=44) vs 4% (n=44) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
9.1% (n=49) vs 4% (n=44) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
7.6% (n=53) vs 1.2% (n=51) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
5.8% (n=42) vs 1.2% (n=51) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
5.4% (n=53) vs -0.8% (n=51) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
9.4% (n=42) vs -0.8% (n=51) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
1% (n=47) vs -0.1% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
4.4% (n=49) vs -0.1% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-1.7% (n=47) vs -0.1% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
5% (n=49) vs -0.1% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-1.7% (n=47) vs -0.1% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
5% (n=49) vs -0.1% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
1% (n=47) vs -0.1% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
4.4% (n=49) vs -0.1% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
1.7% (n=1058) vs -1.3% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
6.1% (n=1058) vs 2.9% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
7.7% (n=1058) vs 4.7% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
7.8% (n=1058) vs 4.4% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
7.5% (n=1058) vs 4.2% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
11.75% (n=92) vs 4.61% (n=88) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
Total Cholesterol -27.9% (n=205) vs -2.9% (n=106) placebo @ 24wk75/150 mg Q2W
percent change · % of baseline
NCT01644175 · Phase 3
show 25 more results
-25.4% (n=205) vs 0.9% (n=106) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
-36.4% (n=41) vs 3.1% (n=21) placebo @ 6wk150 mg Q2W
NCT02326220 · Phase 3
-27.1% (n=41) vs 4.7% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
-29.6% (n=52) vs -10.9% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-30.3% (n=52) vs -12% (n=51) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-19.8% (n=45) vs 6.6% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-19.8% (n=45) vs 6.6% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-25.8% (n=54) vs -3.3% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
-44.7% (n=53) vs -3.3% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
-27.4% (n=273) vs -2.8% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
-33.9% (n=403) vs -13.8% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-34.2% (n=403) vs -14.9% (n=208) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-29.9% (n=49) vs -0.7% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-26.8% (n=287) vs -0.7% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-31.2% (n=97) vs 4% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-32.9% (n=97) vs 2.8% (n=102) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-23.4% (n=49) vs 7.4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-27.7% (n=50) vs 7.4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-25.3% (n=49) vs 7.5% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-27% (n=50) vs 7.5% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-25.3% (n=49) vs 7.5% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-27% (n=50) vs 7.5% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-23.4% (n=49) vs 7.4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-27.7% (n=50) vs 7.4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-35.43% (n=93) vs -7.59% (n=89) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
Fasting TG -13.4% (n=144) vs -1.5% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 53 more results
-15.2% (n=308) vs -0.1% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-12.3% (n=144) vs 1.8% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-13.1% (n=308) vs 0.5% (n=156) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-6% (n=205) vs -5.4% (n=106) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
-11.3% (n=205) vs 3% (n=106) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
-13% (n=467) vs -12.8% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-13% (n=467) vs -12.8% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-11.9% (n=52) vs -10.8% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-12.2% (n=52) vs -2.3% (n=51) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-7.4% (n=45) vs 3.9% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-7.4% (n=45) vs 3.9% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-0.6% (n=54) vs -6.4% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
-18% (n=53) vs -6.4% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
-9.2% (n=58) vs 1.1% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-3% (n=58) vs 2.1% (n=57) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-9.6% (n=322) vs 6.3% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-8% (n=322) vs 1.7% (n=163) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-10.4% (n=166) vs 0.5% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-8.1% (n=166) vs 0.6% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-9.8% (n=37) vs -1.5% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-6.7% (n=76) vs -0.1% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-18.3% (n=37) vs 1.8% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-7.3% (n=76) vs 0.5% (n=156) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-13% (n=273) vs -8.8% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
-14.462% (n=403) vs -14.409% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-9.965% (n=403) vs -13.585% (n=208) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-10.6% (n=115) vs 1.1% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-11.3% (n=115) vs 2.1% (n=57) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-9.3% (n=126) vs -3.6% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-8% (n=126) vs -9.4% (n=122) Ezetimibe @ 12wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-13.6% (n=49) vs 1.9% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-5.7% (n=287) vs 1.9% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-8.143% (n=97) vs -3.627% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-6.999% (n=97) vs 2.113% (n=102) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-15.3% (n=143) vs 6.7% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-13.1% (n=143) vs 2.4% (n=72) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-11.2% (n=48) vs -1.8% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-8.7% (n=53) vs -1.8% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-14% (n=48) vs 8.1% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-10.1% (n=53) vs 8.1% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-12% (n=55) vs -6.7% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-19.1% (n=46) vs -6.7% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-12.4% (n=55) vs -4.7% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-12.1% (n=46) vs -4.7% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
11.9% (n=49) vs 7.7% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-6.8% (n=52) vs 7.7% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-2.2% (n=49) vs 6.5% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-0.3% (n=52) vs 6.5% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-2.2% (n=49) vs 6.5% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-0.3% (n=52) vs 6.5% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
11.9% (n=49) vs 7.7% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-6.8% (n=52) vs 7.7% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-18.37% (n=93) vs -8.85% (n=89) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
LDL-C Target Achievement 78.9% (n=144) vs 9.4% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
responder rate · % of participants
NCT01926782 · Phase 3
show 7 more results
85.2% (n=308) vs 22.2% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
88.6% (n=141) vs 11.3% (n=70) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
89.5% (n=302) vs 22.5% (n=151) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
84.9% (n=37) vs 9.4% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
82.5% (n=76) vs 22.2% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
93% (n=37) vs 11.3% (n=70) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
86.4% (n=75) vs 22.5% (n=151) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3

+ 90 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alirocumab's landscape · Lerodalcibep's landscape